{
  "first_published_at": "2011-08-08", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON125965", 
  "title": "Onsenal▼ (Celecoxib) for familial adenomatous polyposis: withdrawal from EU market", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 141, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/withdrawal_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Onsenal&#9660; (Celecoxib) for familial adenomatous polyposis: withdrawal from EU market</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Onsenal&#9660; (celecoxib) is no longer approved in Europe for the reduction of intestinal polyps in familial adenomatous polyposis (FAP). Furthermore, safety and efficacy data do not support the use of celecoxib in this indication and it should not be used for the unlicensed treatment of FAP<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<h2>Onsenal&#9660; withdrawal</h2><p>Celecoxib is a non-steroidal anti-inflammatory drug and cyclo-oxygenase type 2 inhibitor, which is approved for the treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Until recently, celecoxib was also authorised as the orphan drug Onsenal&#9660; for the reduction of intestinal polyps in familial adenomatous polyposis. At the time of approval of Onsenal&#9660;, the licence (marketing authorisation) holder committed to do post-authorisation clinical studies.</p><p>However, failure to recruit sufficient numbers into a clinical trial designed to provide evidence relating to clinically important benefit has resulted in the licence holder voluntarily withdrawing Onsenal&#9660;.</p><h2>European review of celecoxib in FAP</h2><p>The European Medicines Agency has reviewed the available data after concerns that celecoxib may continue to be used unlicensed in the treatment of FAP. The review concluded that the clinical benefit of celecoxib in FAP has not been sufficiently demonstrated and is outweighed by the increased risk of cardiovascular and gastrointestinal side effects from celecoxib use at high dose and long term in patients with FAP.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Celecoxib is not recommended for the reduction of intestinal polyps in FAP and should not be prescribed for this unlicensed indication</li>\r\n\t\t\t\t<li>Patients who are taking Onsenal&#9660; should consult their doctor as soon as possible to discuss alternative treatment options</li>\r\n\t\t\t</ul></div><h2>Call for reporting</h2><p>Please report suspected adverse reactions through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.</p><p>&nbsp;</p><p><strong>Further information:</strong></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263\">letter for healthcare professionals sent April 2011</a></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001236.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1\" target=\"_blank\">statement on Onsenal withdrawal</a></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/05/WC500106524.pdf\" target=\"_blank\">conclusion on use of celecoxib in FAP</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update vol 5 issue 1, Aug 2011: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<h2>Onsenal&#9660; withdrawal</h2><p>Celecoxib is a non-steroidal anti-inflammatory drug and cyclo-oxygenase type 2 inhibitor, which is approved for the treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Until recently, celecoxib was also authorised as the orphan drug Onsenal&#9660; for the reduction of intestinal polyps in familial adenomatous polyposis. At the time of approval of Onsenal&#9660;, the licence (marketing authorisation) holder committed to do post-authorisation clinical studies.</p><p>However, failure to recruit sufficient numbers into a clinical trial designed to provide evidence relating to clinically important benefit has resulted in the licence holder voluntarily withdrawing Onsenal&#9660;.</p><h2>European review of celecoxib in FAP</h2><p>The European Medicines Agency has reviewed the available data after concerns that celecoxib may continue to be used unlicensed in the treatment of FAP. The review concluded that the clinical benefit of celecoxib in FAP has not been sufficiently demonstrated and is outweighed by the increased risk of cardiovascular and gastrointestinal side effects from celecoxib use at high dose and long term in patients with FAP.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Celecoxib is not recommended for the reduction of intestinal polyps in FAP and should not be prescribed for this unlicensed indication</li>\r\n\t\t\t\t<li>Patients who are taking Onsenal&#9660; should consult their doctor as soon as possible to discuss alternative treatment options</li>\r\n\t\t\t</ul></div><h2>Call for reporting</h2><p>Please report suspected adverse reactions through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.</p><p>&#160;</p><p><strong>Further information:</strong></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263\">letter for healthcare professionals sent April 2011</a></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001236.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">statement on Onsenal withdrawal</a></p><p>European Medicines Agency <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/05/WC500106524.pdf\" target=\"_blank\">conclusion on use of celecoxib in FAP</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update vol 5 issue 1, Aug 2011: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-08-01", 
  "date_last_modified": "2011-08-08", 
  "_assets": [], 
  "_item_id": 141, 
  "summary": "Onsenal▼ (celecoxib) is no longer approved in Europe for the reduction of intestinal polyps in familial adenomatous polyposis (FAP). Furthermore, safety and efficacy data do not support the use of celecoxib in this indication and it should not be used for the unlicensed treatment of FAP", 
  "body": "Article date: August 2011\n\n## Onsenal▼ withdrawal\n\nCelecoxib is a non-steroidal anti-inflammatory drug and cyclo-oxygenase type 2 inhibitor, which is approved for the treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Until recently, celecoxib was also authorised as the orphan drug Onsenal▼ for the reduction of intestinal polyps in familial adenomatous polyposis. At the time of approval of Onsenal▼, the licence (marketing authorisation) holder committed to do post-authorisation clinical studies.\n\nHowever, failure to recruit sufficient numbers into a clinical trial designed to provide evidence relating to clinically important benefit has resulted in the licence holder voluntarily withdrawing Onsenal▼.\n\n## European review of celecoxib in FAP\n\nThe European Medicines Agency has reviewed the available data after concerns that celecoxib may continue to be used unlicensed in the treatment of FAP. The review concluded that the clinical benefit of celecoxib in FAP has not been sufficiently demonstrated and is outweighed by the increased risk of cardiovascular and gastrointestinal side effects from celecoxib use at high dose and long term in patients with FAP.\n\nAdvice for healthcare professionals:  \n  \n  * Celecoxib is not recommended for the reduction of intestinal polyps in FAP and should not be prescribed for this unlicensed indication  \n  * Patients who are taking Onsenal▼ should consult their doctor as soon as possible to discuss alternative treatment options  \n  \n## Call for reporting\n\nPlease report suspected adverse reactions through the Yellow Card Scheme at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/). When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates.\n\n \n\nFurther information:\n\nSee [letter for healthcare professionals sent April 2011](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263)\n\nEuropean Medicines Agency [statement on Onsenal withdrawal](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/04/news_detail_001236.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1)\n\nEuropean Medicines Agency [conclusion on use of celecoxib in FAP](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/05/WC500106524.pdf)\n\n \n\nArticle citation: Drug Safety Update vol 5 issue 1, Aug 2011: A2.\n"
}